Dr Mark Lawrence Feldman, MD in Hudson, NH - Emergency Medicine

Dr Mark Lawrence Feldman, MD is a Emergency Medicine physician based in Hudson, New Hampshire. Dr Mark Lawrence Feldman is licensed to practice in New Hampshire (license number 8283) and his current practice location is 21 Par Ln, Hudson, New Hampshire. He can be reached at his office (for appointments etc.) via phone at (603) 459-9057.

NPI number for Dr Mark Lawrence Feldman is 1700115250 and his current mailing address is 21 Par Ln, Hudson, New Hampshire. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1700115250.

Contact Information

	Dr Mark Lawrence Feldman, MD
	21 Par Ln, Hudson, NH 03051-5215
	(603) 459-9057
	Not Available

Physician's Profile

Full Name	Dr Mark Lawrence Feldman
Gender	Male
Speciality	Emergency Medicine
Location	21 Par Ln, Hudson, New Hampshire
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1700115250
Provider Enumeration Date: 12/11/2009
Last Update Date: 12/11/2009

Medical Identifiers

Medical identifiers for Dr Mark Lawrence Feldman such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1700115250	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207P00000X	Emergency Medicine	8283 (New Hampshire)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Mark Lawrence Feldman is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Mark Lawrence Feldman, MD 21 Par Ln, Hudson, NH 03051-5215 Ph: (603) 459-9057	Dr Mark Lawrence Feldman, MD 21 Par Ln, Hudson, NH 03051-5215 Ph: (603) 459-9057

News Archive

Mylan's Matrix receives tentative FDA approval under PEPFAR for generic Truvada

Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has received the first tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg.

The microorganisms that normally live in the gut can increase body fat

The microorganisms that normally live in the gut can increase body fat, say researchers at Washington University School of Medicine in St. Louis. They found that gut microbes can open the "gates" fat uses to enter the body's fat cells.

Researchers analyze response to combination immunotherapy for patients with rare skin cancer

Harnessing the immune system to treat cancer shows great promise in some patients, but for many, the response does not last long-term.

ANIS2's second edition on ‘micro and nanotechnologies for cancer research' is open for registrations

There is still time until January 8 2010 to register for the second edition of the Alp NanoBio International School (ANIS2), which will be held in Sterzing/Vipiteno (Bozen, Italy) from 11 to 15 of January 2010, organized by the Centre of Excellence LATEMAR - funded by MIUR, in collaboration with the Fondazione Bruno Kessler (FBK).

Air pollution exposure increases preterm birth risk

Exposure to high levels of small particle air pollution is associated with an increased risk of preterm birth - before 37 weeks of pregnancy, according to a new study published online in the journal Environmental Health.

Dr Mark Lawrence Feldman, MD - Emergency Medicine in Hudson, NH